BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that the Board of Directors has appointed Ian T. Clark as Chair of the Board, subject to his election at the company's Annual Meeting of ...

Detailed price information for Biomarin Pharmaceuticals (BMRN-Q) from The Globe and Mail including charting and trades.

This is my fourth BioMarin article following 01/2025's "BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO ...

The score is driven primarily by improving operating fundamentals and cash-flow inflection, but capped by balance-sheet leverage and lack of consistent profitability (negative P/E). Technicals are ...

Some investors are considering whether BioMarin Pharmaceutical's current share price reflects its underlying value, or if the market may be overlooking certain factors. The stock last closed at US$54.

BioMarin Pharmaceutical BMRN reported third-quarter 2025 adjusted earnings per share (EPS) of 12 cents against the Zacks Consensus Estimate of a loss of 15 cents. Quarterly earnings plummeted nearly ...

VOXZOGO contribution to full-year 2025 Total Revenues expected to be in the range of $900 million to $950 million. Refer to Non-GAAP Information beginning on page 10 of this press release for ...

BioMarin Pharmaceutical's (NASDAQ: BMRN) website doesn't show any scheduled events on its calendar over the next month. However, that means nothing. The drugmaker will almost certainly report its 2025 ...

A BioMarin Pharmaceutical study comparing genetic models with newborn screening data from 23 million infants found that models underestimated the prevalence of most rare diseases, in some cases by up ...

SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ ® (pegvaliase-pqpz) met its primary efficacy ...

For the quarter, BioMarin's revenue came in at $776 million, which was 4% higher on a year-over-year basis. Net income not according to generally accepted accounting principles (GAAP), on the other ...

After previously floating the possibility of divesting Roctavian, BioMarin has decided to keep the hemophilia A gene therapy—but with a narrowed focus and cost cuts planned across the drug’s R&D, ...